Stoke Therapeutics, Inc. (STOK) Operating income 2018–2025
Stoke Therapeutics, Inc. (STOK) annual operating income history from SEC filings — each fiscal year as reported.
-$20.6MFY2025 · since FY2018: -$12.8M → -$20.6M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$20.6M | +79.7% |
| FY2024 | -$101.4M | +11.7% |
| FY2023 | -$114.8M | -10.0% |
| FY2022 | -$104.4M | -21.3% |
| FY2021 | -$86.1M | -62.3% |
| FY2020 | -$53.0M | -48.7% |
| FY2019 | -$35.7M | -179.1% |
| FY2018 | -$12.8M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More STOK financial trends
STOK RevenueSTOK Net incomeSTOK Net marginSTOK Gross profitSTOK Gross marginSTOK Operating marginSTOK Operating cash flowSTOK Free cash flowSTOK Capital expendituresSTOK Return on equitySTOK Stock buybacksSTOK Dividends paidSTOK Total assetsSTOK Total liabilitiesSTOK Shareholders’ equitySTOK overview →